You are here

Merck

Top 10 pharma R&D budgets in 2022

Top 10 pharma R&D budgets in 2022

Fierce Biotech

Bristol Myers Squibb

Flag link:

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda

Fierce Pharma

Flag link:

AACR 2023 – Moderna's immunotherapeutic splash

AACR 2023 – Moderna's immunotherapeutic splash

EP Vantage

Moderna Therapeutics

Relay Therapeutics

Vivace Therapeutics

Flag link:

Merck, Viatris agree to settle patent feud surrounding diabetes drugs

Merck, Viatris agree to settle patent feud surrounding diabetes drugs

Endpoints

Flag link:

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

CP WIre

Bristol Myers Squibb

executive compensation

Flag link:

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Bristol Myers Squibb

executive compensation

Flag link:

Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class

Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class

Fierce Biotech

clinical trials

non-small cell lung cancer

metastatic non-small cell lung cancer

Flag link:

Keytruda Unlocked: How Should Merck Proceed with Trials?

Keytruda Unlocked: How Should Merck Proceed with Trials?

BioSpace

clinical trials

Flag link:

Merck asks EMA to reevaluate rejected Covid-19 antiviral

Merck asks EMA to reevaluate rejected Covid-19 antiviral

Endpoints

Flag link:

Merck reports positive data from malignant pleural mesothelioma trial

Merck reports positive data from malignant pleural mesothelioma trial

Clinical Trials Arena

Canadian Cancer Trials Group

clinical trials

Flag link:

In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type

In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type

Fierce Pharma

Bristol Myers Squibb

pleural mseothelioma

clinical trials

Flag link:

Merck pays $50 million for early-stage Epstein-Barr vaccine

Merck pays $50 million for early-stage Epstein-Barr vaccine

BioPharma Dive

Epstein-Barr virus

Flag link:

Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

Endpoints

clinical trials

Flag link:

FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs

FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs

BioPharma Dive

PARP inhibitors

Flag link:

Spotlight – What is next in Nash

Spotlight – What is next in Nash

EP Vantage

clinical trials

Arrowhead Pharmaceuticals

Can-Fite BioPharma

Hepagene Therapeutics

Ligand Pharmaceuticals

Madrigal Pharmaceuticals

NGM Biopharmaceuticals

NorthSea Therapeutics

Sagimet Biosciences

Terns Pharmaceuticals

Viking Therapeutics

Flag link:

AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates

AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates

Fierce Pharma

prostate cancer

Flag link:

Merck reports two Phase 3 study misses for Keytruda

Merck reports two Phase 3 study misses for Keytruda

BioPharma Dive

clinical trials

prostate cancer

Flag link:

Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report

Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report

Fierce Pharma

Boehringer Ingelheim

Flag link:

Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody

Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody

Fierce Biotech

Chipscreen NewWay Biosciences

Flag link:

Warren urges US patent office to scrutinize Merck's efforts with Keytruda

Warren urges US patent office to scrutinize Merck's efforts with Keytruda

Fierce Pharma

Elizabeth Warren

Flag link:

Pages